BioCardia, Inc. (BCDA)

BioCardia's stock price has fluctuated over the past six months. In August 2025, a stock issuance led to a price drop. In September 2025, the company secured financing and regained compliance with Nasdaq. In October and November 2025, patients were enrolled in the Phase 3 CardiAMP HF II trial. November 2025 also saw the release of Q3 financial results and the appointment of a new VP. In December 2025, a new board member was elected, and a consultation with Japan's PMDA was completed. In February 2026, echocardiography data from the CardiAMP HF trial was accepted for presentation.

As a clinical-stage biotherapeutic company, BioCardia, Inc. is primarily focused on research, development, and clinical trials, and there is no readily available information or indication of demand seasonality for its products and services. The demand for its investigational therapies is driven by patient enrollment in clinical trials and regulatory milestones rather than typical market seasonality.

BioCardia, Inc. is a clinical-stage biotherapeutic company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Their pipeline includes CardiAMP® Autologous Cell Therapy for ischemic heart failure and refractory angina, CardiALLO™ Allogeneic Mesenchymal Stem Cell Therapy for ischemic HFrEF and ARDS, the Helix™ Biotherapeutic Delivery System, and Morph® DNA and Avance Steerable Introducers.

BioCardia, Inc. is headquartered in Sunnyvale, California, and primarily conducts its development and clinical trial activities in the United States. The company is also pursuing regulatory pathways internationally, including consultations and preparations for regulatory submissions in Japan for its CardiAMP Cell Therapy.

BioCardia's brand reputation has been influenced by both positive clinical developments and challenges. A negative impact occurred in September 2023 when the CardiAMP HF trial was unlikely to meet its primary efficacy endpoint, causing a stock price drop. A stock issuance in August 2025 also raised concerns. Positive developments, such as clinical results for CardiAMP cell therapy, its FDA breakthrough designation, and progress in regulatory consultations with Japan's PMDA, contribute positively to its reputation.

BioCardia's ownership is distributed among institutional, insider, and retail investors. Institutional investors hold approximately 1.42% to 4.36% of the stock, insiders own about 17.40% to 18.10%, and retail investors hold around 78.89%. Major institutional shareholders include Vanguard Group Inc. and CM Management, LLC. Simon H. Stertzer owns the most shares among individuals. There has been insider buying in the past three months.